BioNTech SE (BNTX) Announces 5M Share Proposed Public Offerings of ADSs and Rights Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioNTech Announces Proposed Public Offerings
July 21, 2020 8:50 AM EDTMAINZ, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- BioNTech SEÂ (Nasdaq: BNTX, BioNTech or the Company) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors.
BioNTech announced the commencement of a firm commitment underwritten offering (the Underwritten Offering) of 5,000,000 American Depositary Shares (ADSs), each representing one of its ordinary shares. In connection with the Underwritten Offering, an... MorePfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
July 20, 2020 8:45 AM EDTThe data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV-2 neutralizing titersBNT162b1 elicited strong CD4+ and CD8+ T cell responses against SARS-CoV-2- receptor binding domain (RBD), compared to baselineThe RBD-specific, interferon-g+, IL-2+, CD8+ T cells elicited by BNT162b1 in immunized participants indicate a strong potential for cell mediated anti-viral activityT cell cytokine profile shows vaccine elicited T cells exhibit a Th1 phenotype, which is... More
